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Introduction: Early detection of malignancies in the lung by less-
invasive methods aims at achieving efficient intervention and sub-
sequently a reduction of the high mortality rate. We investigated 
whether biomarker analysis in endobronchial epithelial-lining fluid 
(ELF) collected by bronchoscopic microsampling (BMS) may be 
useful for a definitive preoperative diagnosis.
Methods: ELF was collected from subsegmental bronchi close to the 
indeterminate pulmonary nodule, which was detected by computed 
tomography, and from the contralateral lung. Diagnosis was confirmed 
by transbronchial biopsy or surgery. The study includes 142 ELF sam-
ples from 51 non–small-cell lung cancer patients and 20 benign cases. 
Microarray analysis was done with a patient subset (n  15) to narrow 
down genes associated with a malignant phenotype. Thirteen poten-
tial biomarkers have been further analyzed by quantitative real-time 
polymerases chain reaction in an independent patient cohort (n  56).
Results: All patients underwent BMS without complications. Gene-
expression analyses by microarrays and quantitative real-time poly-
merases chain reaction could be reliably applied to ELF samples, 
and resulted in potential biomarkers for malignant pulmonary nod-
ules. Four genes (tenascin-C, [C-X-C motif] ligand 14, S100 calcium 
binding protein A9, and keratin 17) were found to be upregulated 
in ELF of non–small-cell lung cancer patients with adenocarci-
noma or squamous cell carcinoma. Combined analysis of tenascin-C 
expression and the nodule size improved the prediction of malig-
nancy in this patient cohort.
Conclusions: our study suggests that the analysis of specific bio-
markers in ELF collected by BMS could be a potentially useful 
adjunct to other diagnostic techniques aiming at the preoperative 
diagnosis of malignant pulmonary nodules.
Key Words: Non–small-cell lung cancer, Solitary pulmonary nod-
ule, Bronchoscopic microsampling, Endobronchial epithelial-lining 
fluid, Surrogate marker.
(J Thorac Oncol. 2012;7: 1001–1008)
Molecular biomarkers in tissues and body fluids  represent a promising source to improve cancer diagnostics and 
risk assessment. In the course of severe diseases like lung 
cancer, early detection of malignancy is needed for successful 
intervention and potential cure. The National Lung Screening 
Trial showed reduced lung cancer mortality with annual 
low-dose spiral computed tomography (CT) compared to 
single-view posteroanterior chest radiography.1 Presently, the 
widespread use of CT in the investigation of respiratory symp-
toms increases the incidental finding of solitary pulmonary 
nodules. However, only a small fraction of screened individu-
als have a malignancy and need intervention. Commonly used 
invasive methods such as biopsy or surgery often detect malig-
nancies, but have the risk for severe side effects, and should 
be avoided in the benign cases.2 We collected endobronchial 
epithelial-lining fluid (ELF) by bronchoscopic microsampling 
(BMS) method.3,4 This approach may have a useful adjunctive 
diagnostic utility in the evaluation of patients with pulmonary 
nodules.5–7 Bronchial epithelial cells, immune cells, and cel-
lular secretions close to the nodule are carefully collected in a 
standardized manner. In contrast to sputum or exhaled breath, 
ELF as a surrogate is strongly linked to the nodule environ-
ment, which may reflect a benign or malignant phenotype 
more reliably. Previously, we reported that the procedure is 
less invasive with a very low complication rate, and feasible in 
routine clinical practice.5 The ability to quantify specific gene 
transcripts in ELF samples was successfully shown in our 
previous study. Here, we screened for tumor-associated genes 
in ELF samples of non–small-cell lung cancer (NSCLC) and 
benign cases by using oligonucleotide microarrays. Potential 
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diagnostic markers were validated in a larger sample cohort. 
We aimed to identify biomarkers that enable the differentia-
tion of malignant and benign lesions in the lung. However, 
potential biomarker might already be affected in benign lung 
epithelium (contralateral site) of the cancer patient, e.g., in 
response to toxic agents.8 Therefore, we also investigated ELF 
from the contralateral bronchial site of all patients to account 
for individual heterogeneity and early disease-related changes 
in the whole lung. Both potential biomarkers and clinical 
parameters were used to improve the diagnosis of indetermi-
nate pulmonary nodules.
PATIENTS AND METHODS
Additional details on the method for making these mea-
surements are provided in the online data supplement (Supple-
mental Digital Content, http://links.lww.com/JTo/A273).
Patient Cohort
The Institutional Review Board approved the data 
collection and analysis, and written informed consent was 
obtained from all patients before the procedure. This study 
included 71 patients with indeterminate solitary pulmonary 
nodules (IPNs). These nodules are confined parenchymal 
lesions with a usual size less than 3 to 4 cm in diameter and 
completely surrounded by aerated lung. These suspicious 
lesions were incidentally found by CT in unselected patients 
with other pulmonary symptoms. Patient characteristics and 
ELF-sampling parameters are given in Table 1. Definitive his-
tological diagnosis was established either by transbronchial 
biopsy or by subsequent surgical resection. Wilcoxon, Fisher’s 
exact and 2 tests were used to compare parameters associated 
with the diagnosis of nodules. Patients were separated into 
a screening (five adenocarcinoma [AC], five squamous cell 
carcinoma [SCC], and five benign cases; n  15), and a vali-
dation cohort (26 AC, nine SCC, one mixed type, four large-
cell lung carcinoma, one carcinoid, and 15 benign cases; n  
56) (Fig. 1). The detailed distribution of cancer and noncancer 
cases is stated in the Supplementary Table 1 (Supplemental 
Digital Content, http://links.lww.com/JTo/A273).
Bronchoscopic Microsampling
BMS was previously described in detail.5 In each 
patient, BMS procedures were repeated twice at the site of the 
lesion (indeterminate pulmonary nodule [IPN]) and at the cor-
responding subsegmental bronchus of the contralateral lung 
(CL) as internal control.
RNA Extraction and Microarray Experiment
Total RNA extraction of ELF samples was performed 
using RNeasy Micro Kit (Qiagen, Hilden, Germany) according 
to the manufacturer’s instructions. The screening study com-
prised 30 ELF samples of matched nodule and contralateral 
site (15 individuals). Total RNA (150 ng) was amplified using 
GeneChip 3’ IVT Express Kit (Affymetrix, Santa Clara, CA). 
The microarray platform, labeling, hybridization, scanning, 
and normalization were previously described.9 Linear models 
for microarray (LIMMA) data software package were used 
to identify differentially expressed genes.10 Briefly, empirical 
Bayes shrinkage of the gene-wise residual variances ensures 
stable results (score for differentially expressed genes) even 
when the number of arrays is small. The comparison between 
TABLE 1. Clinical and Demographic Characteristics of the 
Patient Cohort
Parameter Tumor (n  51) Benign (n  20) Test (p Value)
Diagnosis
 Adenocarcinoma 31 NA NA
 Squamous cell 
carcinoma
14 NA NA
 other (LCLC) 6 (4) NA NA
 Benign  20 NA
 Median age, yr 68  7.3 60  10.9 0.0119a
Sex
 Male 30 9 0.4269b
 Female 21 11
Smoking
 yes 38 14 0.7263b
 No 8 4
 Unavailable 5 2 NA
 Median nodule  
 diameter, mm
32.0  13.1 22.6  6.4 0.0004a
Sampling distance
 20 mm 41 13 0.3425b
 20 mm 10 6
 Unavailable 0 1 NA
Nodule location
 LLL/LUL 13/9 3/3 1.0000c
 RLL/RML/RUL 8/4/17 6/3/3 0.1466c
 Unavailable 0 1 NA
a Wilcoxon test.
b Fisher’s test.
c 2 test.
Bold text indicates significant p value  0.05.
NA, not applicable; LCLC, large-cell lung carcinoma; LLL, left lower lobe; LUL , 
left upper lobe; RLL, right lower lobe; RML, right middle lobe; RUL, right upper lobe.
FIGURE 1. Study design of ELF biomarker discovery and 
validation for early NSCLC detection. ELF, epithelial lining 
fluid; NSCLC, non–small-cell lung cancer.
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tumor (or AC and SCC, separately) versus benign diagnosis 
was done by using microarray data from ELF of the nodule site 
(IPN) or both locations (IPN and CL) of each patient. From 
each candidate-gene list, the 20 best-ranked genes were prese-
lected by the LIMMA score (local p value  0.05) and fold 
change criterion ( two-fold). Finally, 10 candidate genes were 
selected for validation with regard to the increased expression in 
patients with cancer diagnosis and prior knowledge of putative 
gene function in NSCLC, tumor microenvironment, or immune 
system. Three more genes (MMP9, S100A8, and S100 calcium 
binding protein A9 [S100A9]) were additionally introduced into 
validation on the basis of our previous gene-expression studies 
in NSCLC.5,9
Quantitative Real-Time PCR
The validation study comprised 112 matched IPN and 
contralateral ELF extracts of the same patients (n  56). 
Relative quantification was done using two internal con-
trol genes esterase D and polymerases 2A as previously 
described.5 A detailed list of examined genes and assay infor-
mation is given in Supplementary Table 2 (Supplemental 
Digital Content, http://links.lww.com/JTo/A273). Statistical 
analysis was done using the paired or unpaired Wilcoxon test, 
respectively. The comparison between malignant and nonma-
lignant phenotypes was done by using normalized Ct values 
from ELF of a distinct location (IPN or CL, unpaired test), by 
accounting for both locations (IPN or CL, unpaired test), or 
by directly comparing both locations (IPN versus CL, paired 
test). Genes were regarded to be differentially expressed with 
a p value  0.05 and a fold change less than 0.5 or more than 
2. We accounted for the interaction between biomarker expres-
sion and significant clinical parameters (nodule diameter and 
age) by using analysis of variance analysis. The discrimina-
tive efficacy of various parameters (nodule diameter, tenas-
cin-C [TNC] expression, and multiplying both values) was 
analyzed by receiver operating characteristics curves using 
the area under the curve (AUC) as a measure. The microar-
ray and the quantitative real-time polymerase chain reaction 
TABLE 2. Selected Biomarker Candidates in ELF by Microarray Analysis
Gene Symbol Affy ID Associated Process Group Comparison p Valuea Ratio
CXCL14 222484_s_at Immune system IPN adeno vs. benign 0.003996 11.71
IPN/CL adeno vs. benign 0.000953 21.31
IFITM1 201601_x_at Immune system IPN/CL adeno vs. benign 0.000665 5.31
KRT17 212236_x_at NSCLC IPN SCC vs. benign 0.001621 4.27
IPN/CL SCC vs. benign 0.001333 3.09
IPN/CL tumor vs. benign 0.000283 3.04
MyC 202431_s_at NSCLC IPN adeno vs. benign 0.006268 2.05
IPN tumor vs. benign 0.00066 2.32
SDC1 201286_at NSCLC IPN adeno vs. benign 0.002441 2.15
IPN tumor vs. benign 0.000214 2.53
IPN/CL adeno vs. benign 0.000210 3.16
IPN/CL SCC vs. benign 0.001033 2.59
IPN/CL tumor vs. benign 0.000094 2.86
SERPINB13 211361_s_at Tumor environment IPN SCC vs. benign 0.000259 5.92
IPN tumor vs. benign 0.001855 3.91
SFN 33323_r_at NSCLC IPN tumor vs. benign 0.002395 2.58
IPN/CL SCC vs. benign 0.000976 3.29
IPN/CL tumor vs. benign 0.000268 3.12
SULF2 224724_at NSCLC IPN/CL adeno vs. benign 0.00028 3.29
IPN/CL SCC vs. benign 0.000596 2.97
IPN/CL tumor vs. benign 0.000065 3.12
TNC 201645_at Tumor environment IPN adeno vs. benign 0.000835 6.12
IPN SCC vs. benign 0.000849 6.09
IPN tumor vs. benign 0.000142 6.11
IPN/CL adeno vs. benign 0.000970 5.3
TP63 209863_s_at NSCLC IPN/CL adeno vs. benign 0.000788 6.03
IPN/CL tumor vs. benign 0.000553 4.91
Genes were assigned upon microarray analysis for the significance in the LIMMA test for six different group-wise comparisons, all tumor samples, adenocarcinoma only or 
squamous cell carcinoma only against benign samples independent (IPN only) or dependent of the contralateral site (IPN/CL).
a LIMMA analysis.
IPN, indeterminate pulmonary nodule; CL, contralateral site; Adeno, adenocarcinoma; SCC, squamous cell carcinoma; NSCLC, non–small-cell lung cancer; LIMMA, Linear 
models for microarray.
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(qRT-PCR) data were deposited into the National Center for 
Biotechnology Information Gene Expression omnibus data-
base as super series (GSE27554) such that they were compliant 
with Minimum Information About a Microarray Experiment.
RESULTS
BMS, Diagnosis, and Clinical Parameters
The study included 71 consecutive patients with fluoro-
scopically visible IPNs. The collective comprised 51 patients 
with a tumor and 20 individuals with a benign diagnosis of the 
IPN (Table 1). AC and SCC were the most frequent malignant 
diagnoses (45 of 51 cases, 88%). For benign findings hamar-
tochondroma and subtypes were diagnosed in 10 of 20 cases 
(50%). The collective (malignant/benign) includes 39 (30/9) 
men and 32 (21/11) women with a median age of 67 (68/60) 
years. The median nodule diameter was 28.1 mm (32.0/22.6). 
For 54 (41/13) patients, the distance of sampling was below 20 
mm from the nodule. In this study, a larger nodule diameter 
(p = 0.0004) and an increase in age (p = 0.01) was associated 
with the tumor diagnosis. All patients successfully underwent 
BMS without complications traced back to the procedures.
Microarray-Based Biomarker Screening in 
Endobronchial ELF
Total RNA recovery and quality from ELF samples was 
heterogeneous and ranged between 75 and 600 ng and RIN 
(RNA integrity number) values of one to seven, respectively. 
Therefore, we used RNA samples of higher quantity (200 
ng) and quality (RIN  5) for microarray screening experi-
ments (n  30) and all other ELF samples for qRT-PCR 
validation (n  112). Microarray analysis did not reveal sig-
nificantly differentially expressed genes between malignant 
and nonmalignant specimens in any comparison using mul-
tiple testing correction. Therefore, 20 of the 100 best ranked 
genes of each LIMMA test, in total 67 nonredundant genes, 
were prioritized as biomarker candidates as a result of the 
LIMMA score (local p value  0.05) andthe higher expres-
sion (fold change  2) in ELF close to malignant versus non-
malignant nodules (See SupplementaryTable 3, Supplemental 
Digital Content, http://links.lww.com/JTo/A273). Twenty-
seven of 67 genes (40%) were identified in different compari-
sons. The further selection of 10 candidate genes was based on 
the following criteria: best and most frequent ranked across all 
comparisons; the fold change; and prior knowledge of puta-
tive gene function in NSCLC disease. For example, TNC was 
best ranked in AC, SCC, and both together, compared to the 
benign phenotype. For the validation, we focused on the genes 
that were reported to be involved in NSCLC (MYC, keratin 17 
[KRT17], SULF2, SFN, SDC1, and TP63), in tumor-stroma 
interaction (TNC and SERPINB13), or in the regulation of 
the immune system (IFITM1 and [C-X-C motif] ligand 14 
[CXCL14]), respectively (Table 2). Three other genes (MMP9, 
S100A8, and S100A9) were selected on the basis of our previ-
ous gene-expression studies in NSCLC.5,9
qRT-PCR Performance for Biomarker Detection 
in ELF Samples
The expression of 15 genes was successfully measured 
in 112 ELF samples using qRT-PCR (Supplementary Table 
2, Supplemental Digital Content, http://links.lww.com/JTo/
A273). The median expression for all genes was in a reliable 
range (Ct values, 21.9–34.4). The SD of the technical dupli-
cates was low ( 0.5) in the majority of the measurements 
(94%). Increased variances (SD  0.5) were only obtained 
for the two genes MMP9 (39%) and SERPINB13 (19%). Both 
TABLE 3. Target Genes in ELF Samples of Nodules (IPN) with Malignant or Nonmalignant Diagnosis
Gene
IPN Tumor vs. Benign IPN Adeno vs. Benign IPN SCC vs. Benign IPN Adeno vs. SCC
p Valuea Ratio p Valuea Ratio p Valuea Ratio p Valuea Ratio
TNC 0.000467 2.28 0.001894 2.08 0.002146 2.90 0.230800 0.72
CXCL14 0.051420 2.54 0.081120 2.19 0.032750 9.44 0.148500 0.23
S100A9 0.285600 1.35 0.654000 1.28 0.038740 3.82 0.085980 0.34
KRT17 0.002131 1.63 0.007505 1.52 0.021170 2.78 0.110500 0.55
SULF2 0.061170 1.37 0.042780 1.36 0.411500 1.37 0.697000 0.99
S100A8 0.191100 0.46 0.201100 0.50 1.000000 0.39 0.540100 1.28
IFITM1 0.217700 1.45 0.134300 1.68 0.558400 1.12 0.926200 1.49
SDC1 0.262200 1.43 0.288700 1.41 0.289500 2.27 0.515700 0.62
SFN 0.419700 1.14 0.799500 1.05 0.122700 1.77 0.109700 0.59
TP63 0.530700 0.81 0.472200 0.93 0.263100 1.24 0.355300 0.75
SERPINB13 0.732700 1.17 0.696300 1.15 0.829000 1.49 1.000000 0.77
MyC 0.741800 1.04 0.841000 1.03 0.108500 1.54 0.101300 0.67
MMP9 0.807200 1.29 0.882800 1.28 0.639900 2.37 0.901800 0.54
In the validation study genes was tested for significance in different comparisons only using the nodule-site measurements. The four genes TNC, CXCL14, S100A9, and KRT17 
showed significant difference in at least one comparison.
IPN, indeterminate pulmonary nodule; Adeno, adenocarcinoma; SCC, squamous cell carcinoma.
a Wilcoxon test.
Bold text indicates significant genes with p value  0.05 and fold change  2.
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genes showed the lowest expression across all ELF samples 
(Ct values, 32.3–34.4). only in nine of 1792 technical dupli-
cate measurements (0.5%), the detection limit was achieved 
(Ct value  40). In summary, none of the genes or ELF sam-
ples had to be excluded from the analysis. In the following, 
potential marker genes were analyzed in ELF by taking into 
account different sampling locations. Gene expression values 
were used either from the nodule site only, both the nodule and 
the contralateral site, or the contralateral site only in order to 
perform three different comparisons and statistical tests.
Expression of Putative Diagnostic Markers in 
ELF Samples Close to Pulmonary Nodules
First, we searched for potential diagnostic markers in 
ELF samples close to the nodule. TNC was identified to be 
significantly upregulated (p value = 0.0005, fold change = 2.3) 
in ELF samples close to nodules with malignant phenotype 
(Table 3). Increased expression of TNC was observed for both 
AC and SCC, respectively (Fig. 2A). Furthermore, the gene 
chemokine CXCL14 was higher expressed in ELF samples of 
SCC patients compared to benign cases (p value = 0.03, fold 
change = 9.4). Differential expression of CXCL14 was slightly 
above the significance level in patients with AC or across all 
NSCLCs. Two genes, S100A9 and KRT17, were found to be 
higher expressed in ELF samples of SCC patients.
Second, we accounted for the gene-expression vari-
ance on the contralateral site of each individual before the 
statistical test. Differential expression of TNC between 
malignant and benign cases was less significant (p value = 
0.013, fold change = 1.9) when the contralateral site was 
FIGURE 2. A, TNC gene-expression difference between ELF samples of malignant (SCC and AC) and benign diagnosis  
including all nodules, (B), or only nodules smaller than 25 mm in diameter. C, Distribution of individual TNC expression 
and nodule diameter across 41 malignant and 15 benign cases. TNC, Tenascin-C; ELF, epithelial-lining fluid.
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taken into account (Table 4). In contrast, the result for 
CXCL14 was more significant when the contralateral site 
was taken into account. No further potential biomarkers 
were identified in both analyses. In summary, the added 
value of ELF samples from the contralateral site as the 
potential individual background was low with regard to the 
quantified transcripts.
Gene-Expression Variances in ELF Samples of 
the Nodule and the Contralateral Site
The comparison between ELF samples of the nod-
ule and the corresponding contralateral site of each patient 
revealed significantly higher expression of the genes MMP9, 
S100A8, S100A9, IFITM1, and TNC (Supplementary Table 
4, Supplemental Digital Content, http://links.lww.com/
JTo/A273). However, for the genes MMP9, S100A8, and 
S100A9, a similar expression difference was observed in the 
case of malignant and nonmalignant diagnosis. Thus, these 
genes were commonly upregulated in ELF samples close to 
the nodule site, but not reliable for diagnosis. In contrast, 
IFITM1 was upregulated in patients with AC, whereas TNC 
was upregulated in patients with SCC when comparing the 
nodule and the contralateral site. Both genes (TNC and 
IFITM1) were less or not deregulated in the case of nonma-
lignant nodules.
None of the most promising biomarker candidates (TNC 
and CXCL14) were differentially expressed between malig-
nant and nonmalignant phenotypes using ELF only from the 
contralateral site. of the 13 investigated candidates, only the 
gene S100A9 was significantly upregulated in ELF samples 
from the contralateral site of SCC patients (Supplementary 
Table 5, Supplemental Digital Content, http://links.lww.com/
JTo/A273). This finding indicates potential occurrence of 
early molecular changes during NSCLC onset.
Multivariate Analyses Using TNC Gene 
Expression, Nodule Size, and Age for Early 
Detection of NSCLC
We reported earlier that increased age and a larger nodule 
diameter upon CT diagnosis were significantly associated with 
the tumor diagnosis in our collective (Table 1). Furthermore, 
TNC expression was significantly associated with malignant 
diagnosis (Table 3). To this fact, analysis of variance was con-
ducted to unravel added value of biomarker expression for IPN 
diagnosis. A significant result was observed for TNC expres-
sion when introduced into the model with age (p  0.005) or 
nodule diameter (p  0.019). None of the other genes showed 
significant additive effects (not shown). Similarly, we excluded 
the impact of the nodule size by analyzing only patients (n = 
24) with a nodule smaller than 25 mm. In contrast to the nod-
ule size (p value  0.81), TNC expression difference between 
malignant and benign diagnosis still reached the significance 
level (p value  0.05) (Fig. 2B). This finding was underlined 
by the comparison of TNC expression value and nodule diam-
eter in all patients (Fig. 2C). The coefficient of correlation was 
low in NSCLC (r  0.37) or benign diagnoses (r  0.35). The 
diagnostic potential of the two most promising parameters 
(nodule diameter and TNC expression) was further evaluated 
in the receiver operating characteristic analysis (Table 5). The 
power to discriminate between benign and malignant nodules 
increased when combining both parameters (TNC expression  
TABLE 4. Target Genes in ELF Samples of Nodules With Malignant or Nonmalignant Diagnosis Dependent on the Paired 
Contralateral Site (Ratio IPN/CL)
Gene
IPN/CL Tumor vs. Benign IPN/CL Adeno vs. Benign IPN/CL SCC vs. Benign IPN/CL Adeno vs. SCC
p Valuea Ratio p Valuea Ratio p Valuea Ratio p Valuea Ratio
CXCL14 0.025750 2.82 0.019470 2.81 0.012970 4.65 0.183700 0.61
TNC 0.012530 1.89 0.020670 1.78 0.002146 4.74 0.093640 0.38
SULF2 0.135100 1.23 0.149100 1.22 0.108500 1.37 0.616400 0.89
SDC1 0.339800 1.10 0.264800 1.11 0.173700 1.21 0.323300 0.91
KRT17 0.225500 1.06 0.243900 1.11 0.215200 1.04 0.673100 1.07
S100A8 0.321400 0.61 0.242200 0.37 0.519500 5.17 0.159600 0.07
TP63 0.363300 1.29 0.332300 1.29 0.263100 1.39 0.673100 0.93
MyC 0.582700 1.09 0.841000 1.05 0.073190 1.50 0.060890 0.70
SFN 0.673700 1.15 0.925400 1.04 0.040860 1.58 0.016330 0.65
MMP9 0.930000 1.05 0.906100 1.45 0.815300 2.80 0.967200 0.52
S100A9 0.428400 0.48 0.205600 0.45 0.249600 2.70 0.140000 0.17
SERPINB13 0.930000 0.94 0.633200 0.91 0.476700 1.02 0.215800 0.90
IFITM1 1.000000 1.29 0.678400 1.42 0.639900 1.04 0.361600 1.36
In the validation study genes was tested for significance in different comparisons using the paired measurements of the nodule and the contralateral site. The four genes TNC, 
CXCL14, S100A9, and KRT17 showed significant difference in at least one comparison.
IPN, indeterminate pulmonary nodule; CL, contralateral site; Adeno, adenocarcinoma; SCC, squamous cell carcinoma.
a Wilcoxon test.
Bold text indicates significant genes with p value  0.05 and fold change  2.
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nodule diameter) (AUC  0.84, p value  0.0001) compared 
to TNC expression (AUC  0.78, p value  0.0014) or nodule 
diameter (AUC  0.79, p value  0.0009) alone.
DISCUSSION
Previous studies showed that ELF collected close the 
pulmonary nodule is valid to reflect molecular characteristics 
of potential malignancy.5–7 Tumor markers like carcinoembry-
onic antigen and cytokeratin fragment 21-1 were found to be in 
higher abundance in ELF close to small peripheral lung carci-
noma when compared to the contralateral site or benign cases.6 
Recently, DNA hypermethylation of tumor-suppressor genes 
like p16 and RARB, and EGFR mutations could be detected 
in both the tumor tissue and the corresponding ELF sample, 
but rarely on the contralateral site or in the serum of the same 
patients.7 Both reports supported the need of ELF sampling 
close to the pulmonary nodule to reflect genetic alterations 
and their consequences in early-stage malignancies.
In a previous study, we conducted ELF sampling in 
NSCLC patients and measured the expression of cancer- 
related genes.5 For example, MMP9 was strongly upregulated 
in ELF samples close to malignant nodules compared to the 
contralateral site. In the current study, this finding was success-
fully verified in an independent, larger collective. However, 
higher expression of MMP9 close to the nodules was not 
restricted to patients with a malignant diagnosis. one explana-
tion for this finding may be that increased expression of MMP9 
is not restricted to NSCLC, but it is also associated with non-
malignant lung diseases like fibrosis and chronic obstructive 
pulmonary disease, or tissue remodeling in general.11,12 In this 
regard, MMP9 may be a useful marker for sampling quality in 
the sense of nodule proximity.
our biomarker screening aimed to narrow down genes 
of interest in ELF samples with respect to early NSCLC detec-
tion. The statistical power of the microarray data analysis was 
restricted by the small screening cohort because of the limited 
biomaterial and the higher variance of the overall gene expres-
sion across the ELF samples. However, in contrast to previ-
ous ELF studies focusing on known putative biomarkers, our 
approach enabled us to identify robustly measurable novel tar-
get genes, which could be fairly validated in independent ELF 
samples. We identified and validated TNC as the most promis-
ing biomarker to detect malignant pulmonary nodules. TNC 
was significantly higher expressed in ELF samples close to 
NSCLC compared to benign nodules. No differences in TNC 
expression were observed when only ELF of the contralateral 
site was taken into account. TNC is an important component 
of the extracellular matrix, and is involved in tissue remodel-
ing and cell signaling.13–15 The glycoprotein is highly abundant 
during embryogenesis and in early lung development, but is 
expressed only at low levels in normal adult tissues. In various 
tumor entities, including NSCLC, TNC was found to be dereg-
ulated on transcriptomic and protein levels.16,17 The putative 
role of TNC in cancer may probably occur in an early phase 
of carcinogenesis. It was shown that low TNC expression in 
transgenic mice was associated with decreased primary tumor 
growth, a lower tumor relapse rate, and reduced incidence of 
lung metastasis.18 Higher expression of TNC in breast cancer 
cells infiltrating the lung was associated with the aggressive-
ness of pulmonary metastasis.19 Furthermore, TNC may activate 
essential processes in the tumor environment, like the remod-
eling of extracellular matrix or the inhibition of lymphocytic 
infiltration.14,17 These processes are known to promote inva-
sion, cell migration, tumor immune evasion, and recurrence. 
Thus, early tumor development in the lung may be reflected by 
increased TNC expression in the environment, which was suc-
cessfully analyzed by our ELF-sampling approach.
The abundance of potential biomarkers can vary between 
the tumor cells and their environment. After screening and 
validation, we identified a higher expression of CXCL14 in the 
environment of malignancies. In contrast, CXCL14 has been 
described to be commonly silenced in AC, and re-expression 
induces tumor necrosis.20 CXCL14 methylation was also found 
in sputum from asymptomatic early-stage lung cancer cases, 
and therefore was suggested to be a diagnostic biomarker.20 
Furthermore, CXCL14 was attributed an important role as a 
potent angiostatic chemokine, which is involved in angiogen-
esis and tumor immunity.21,22 Although the same biomarker 
candidate was identified by two different approaches, higher 
CXCL14 expression in ELF may be caused by tumor-associated 
processes like immune cell infiltration or tissue remodeling 
rather than reflecting the gene-expression variance of the 
tumor cells.
Two further genes (KRT17 and S100A9) were higher 
expressed in ELF of patients who suffered from SCC. Both 
genes were already described to be upregulated in SCC com-
pared to AC tissues.9 For S100A9, we also detected higher 
expression in ELF samples from the contralateral site of SCC 
patients. The S100 chemokine is activated in premetastatic 
niches in the lung,23 and may also clear the way for early car-
cinogenesis. The expression change of genes in pulmonary 
tissues distant from the tumor may also be the consequence of 
field cancerization.8
our results indicate that TNC expression and the nodule 
size are two independent predictive factors for the diagnosis of 
NSCLC. However, this finding has to be verified in larger cohorts. 
A combination of molecular and clinical parameters may be 
useful for lung cancer diagnostics, which has been already sug-
gested based on gene-expression analysis in AC tissues.24 The 
gene-expression analysis of ELF samples from the contralat-
eral site, which aimed to correct for the individual background, 
mostly impaired the findings and did not allow the detection 
of additional biomarkers. Intraindividual genetic heterogeneity, 
sampling variances, and the absence of tumor-associated 
TABLE 5. ROC Analysis for TNC Expression and Nodule Size
ROC Analysis
TNC 
Expression
Nodule 
Diameter
Nodule Diameter 3 
TNC Expression
Area 0.7805 0.7927 0.8374
Standard error 0.0639 0.0638 0.05257
95% confidence 
interval
0.6552–0.9058 0.6676–0.9178 0.7343–0.9405
p value 0.001424 0.0008737 0.000125
RoC analysis was done for three different parameters, the TNC gene-expression 
value, nodule diameter, and the multiplication of both values. RoC analyses were 
significant (p value  0.05) with an area under curve between 0.78–0.84.
RoC, receiver operating characteristic; TNC, tenascin-C.
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molecular field effect in bronchi distant to malignant nodules 
may explain this limitation. Notably, sensitivity and specificity 
of biomarkers detected on the nodule site might be increased by 
analyzing distinct transcript variants. For example, TNC exists 
as multiple alternatively spliced isoforms. The ENSEMBL 
database (Release 60, http://www.ensembl.org) describes seven 
protein-coding and five noncoding splice variants. Several of 
these are expressed in a tumor-specific manner.25 Therefore, 
a deeper analysis of TNC transcript variants in ELF samples 
may improve the diagnostic accuracy. Furthermore, TNC in 
serum was already suggested as a potential predictive marker of 
angiogenesis in NSCLC.26 With regard to the multiple functions 
during tumorigenesis, TNC may not only represent a potential 
diagnostic target for early lung cancer detection, but it may also 
play a role in cancer progression and therapy response.
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